Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Schedule of Segment Information (Details)

v3.20.4
Segment Information - Schedule of Segment Information (Details) - USD ($)
3 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Oct. 31, 2020
Net Loss $ (2,232,377) $ (2,616,575)  
Total operating costs and expenses 2,745,631 2,629,869  
Less non-cash share-based compensation (986,099) (1,021,334)  
Operating costs and expenses excluding non-cash share-based compensation 1,759,532 1,608,535  
Total assets 14,604,402 9,452,964 $ 9,452,964
CAR-T Therapeutics [Member]      
Net Loss (960,736) (630,333)  
Operating costs and expenses excluding non-cash share-based compensation 557,680 346,341  
Total assets 5,849,920 2,988,124  
Cancer Vaccines [Member]      
Net Loss (906,336) (195,596)  
Operating costs and expenses excluding non-cash share-based compensation 537,988 98,270  
Total assets 5,822,106 946,923  
Anti-Viral Therapeutics [Member]      
Net Loss (480,806)  
Operating costs and expenses excluding non-cash share-based compensation 270,256  
Total assets 2,775,760 2,464,361  
Cancer Diagnostics [Member]      
Net Loss (8,962) (1,790,646)  
Operating costs and expenses excluding non-cash share-based compensation 6,432 1,163,924  
Total assets 85,463 2,869,529  
Patent Licensing [Member]      
Net Loss 124,463  
Operating costs and expenses excluding non-cash share-based compensation 387,176  
Total assets $ 71,153 $ 184,027